Vertex Pharmaceuticals price target raised to $545 from $520 at BMO Capital
BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...
BMO raises Vertex stock price target to $545 from $520
BMO Capital Markets increased its price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares, moving the ...